We sought to describe and analyze discrepancies between sexes in the outcomes of patients hospitalized for ruptured abdominal aortic aneurysms (rAAA) by conducting a retrospective analysis of the Nationwide Inpatient Sample. The review included all adult patients (≥18 years old) hospitalized with a primary diagnosis of rAAA between January 2002 and December 2014. In-hospital mortality differences between females and males were analyzed overall and separately among those receiving endovascular AAA repair (EVAR) or open AAA repair (OAR). In-hospital mortality for females declined from 61.0% in 2002 to 49.0% in 2014 (P for trend <0.001), while mortality for males declined from 48.6% in 2002 to 32.2% in 2014 (P for trend <0.001). Among those receiving EVAR, females were significantly more likely to die in the hospital than males (adjusted odds ratio [OR], 1.44; 95% CI, 1.12–1.84). In addition, the odds of mortality among those receiving OAR were higher for females than males (adjusted OR, 1.14; 95% CI: 1.00–1.31). These data provide evidence that despite overall decreasing trends in mortality for both sexes, females remain at higher risk of death compared with males regardless of surgical repair procedure.
Launched in 1994, Deerfield Management Company is an investment firm dedicated to advancing healthcare through information, investment, and philanthropy—all toward the end goal of cures for disease, improved quality of life, and reduced cost of care.
Read More
Investment
Supporting companies across the healthcare ecosystem with flexible funding models…
Read MoreFeatured
Deerfield Management and the University of North Carolina Eshelman School of Pharmacy Launch Biotherapeutics Certificate Program Bridging Academia and Industry Deerfield Management Launches Joint Venture with Horizon Blue Cross Blue Shield of New Jersey Elion Therapeutics Closes $81 Million Series B Funding Round Led by Deerfield Management and AMR Action Fund
Portfolio Companies
Deerfield generally maintains a combined portfolio of more than 150 private and public investments across the life science, medical device, diagnostic, digital health and health service industries at all stages of evolution from start-up to mature company.
Read More View Portfolio Companies
Research Collaborations
Deerfield partners with leading academic research centers, providing critical funding and expertise to further sustain and accelerate the commercialization of discoveries toward meaningful societal impact by advancing cures for disease.
Read More View Research Collaborations
Strategic Partners
As a strategic partner, Deerfield offers capital, scientific expertise, business operating support, and unique access to innovation.
Read More
Deerfield Foundation
The Deerfield Foundation is a New York City-based not-for-profit organization whose mission is to improve health, accelerate innovation and promote human equity.
Read More Meet the Foundation TeamFoundation Partners by Focus
Children's Health Diversity Initiatives Maternal Health View AllFounded Diversity Programs
Break into the Boardroom Fellowships Science to the Street (formerly Women in Science)
Cure Campus
Cure is a 12-story innovation campus in New York City that intends to bring together innovators from academia, government, industry, and the not-for-profit sectors to advance human health and accelerate the fight against disease.
Read More Join the Cure Email ListCure Programming
Cure has a series of expert lectures intended to advance thought in healthcare, management, innovation, policy, and other relevant subjects. This fosters growth and education for those at Cure and its guests.
Events at the Cure
